$NMRD
Nemaura Medical Inc. Stock $nmrd

$nmrd Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000107997322001446 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$3.017K	$74.03K	$0.00
YoY Change	-98.36%
Cost Of Revenue	$2.971K	$72.36K	$0.00
YoY Change	-98.28%
Gross Profit	$46.00	$1.670K	$0.00
YoY Change	-99.59%
Gross Profit Margin	1.52%	2.26%
Selling, General & Admin	$239.6K	$2.320M	$1.428M
YoY Change	-82.78%	62.47%	85.44%
% of Gross Profit	520934.78%	138920.36%
Research & Development	$393.7K	$257.1K	$286.9K
YoY Change	-4.51%	-10.4%	-37.63%
% of Gross Profit	855971.74%	15392.87%
Depreciation & Amortization	$95.92K	$73.89K	$45.56K
YoY Change	65.21%	62.18%	127.8%
% of Gross Profit	208521.74%	4424.55%
Operating Expenses	$633.4K	$2.577M	$1.715M
YoY Change	-64.88%	50.28%	39.41%
Operating Profit	-$633.3K	-$2.575M	-$1.715M
YoY Change	-64.67%	50.18%
Interest Expense	-$1.083M	-$1.503M	-$1.779M
YoY Change	-33.93%	-15.53%	408.42%
% of Operating Profit
Other Income/Expense, Net	$273.00	$0.00
YoY Change	-93.77%
Pretax Income	-$1.716M	-$4.078M	-$3.494M
YoY Change	-49.99%	16.72%	121.16%
Income Tax
% Of Pretax Income
Net Earnings	-$1.716M	-$4.078M	-$3.494M
YoY Change	-49.99%	16.72%	121.16%
Net Earnings / Revenue	-56886.91%	-5509.45%
Basic Earnings Per Share	-$0.07	-$0.16
Diluted Earnings Per Share	-$0.07	-$169.2K	-$149.9K
COMMON SHARES
Basic Shares Outstanding	24.10M shares	24.10M shares	23.31M shares
Diluted Shares Outstanding	24.10M shares	24.10M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.341M	$10.11M	$26.77M
YoY Change	-68.15%	-62.23%	57.92%
Cash & Equivalents	$7.341M	$10.11M	$26.77M
Short-Term Investments
Other Short-Term Assets	$1.217M	$1.934M	$1.364M
YoY Change	157.69%	41.75%	279.02%
Inventory	$2.352M	$1.910M	$1.115M
Prepaid Expenses
Receivables	$25.32K	$0.00	$503.6K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.94M	$13.95M	$29.75M
YoY Change	-56.35%	-53.1%	67.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$581.9K	$521.8K	$351.5K
YoY Change	28.1%	48.44%	134.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.026M	$1.949M
YoY Change
Total Long-Term Assets	$2.026M	$1.949M	$1.843M
YoY Change	0.37%	5.77%	372.46%
TOTAL ASSETS
Total Short-Term Assets	$10.94M	$13.95M	$29.75M
Total Long-Term Assets	$2.026M	$1.949M	$1.843M
Total Assets	$12.96M	$15.90M	$31.59M
YoY Change	-52.12%	-49.67%	74.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$171.2K	$301.1K	$151.4K
YoY Change	-3.06%	98.89%	-5.38%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.51M	$17.40M	$15.83M
YoY Change	-22.48%	9.91%	551.43%
Total Short-Term Liabilities	$13.22M	$20.47M	$17.21M
YoY Change	-18.07%	18.94%	495.45%
LONG-TERM LIABILITIES
Long-Term Debt	$8.558M	$3.491M	$8.795M
YoY Change	-1.78%	-60.31%	215.23%
Other Long-Term Liabilities	$1.043M	$955.9K	$1.225M
YoY Change	-13.23%	-21.95%	2.07%
Total Long-Term Liabilities	$9.600M	$4.447M	$10.02M
YoY Change	-3.17%	-55.62%	151.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.22M	$20.47M	$17.21M
Total Long-Term Liabilities	$9.600M	$4.447M	$10.02M
Total Liabilities	$22.82M	$24.91M	$27.23M
YoY Change	-12.4%	-8.5%	296.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.19M	-$45.79M
YoY Change
Common Stock	$38.32M	$38.32M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.859M	-$9.012M	$4.366M
YoY Change
Total Liabilities & Shareholders Equity	$12.96M	$15.90M	$31.59M
YoY Change	-52.12%	-49.67%	74.46%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.716M	-$4.078M	-$3.494M
YoY Change	-49.99%	16.72%	121.16%
Depreciation, Depletion And Amortization	$95.92K	$73.89K	$45.56K
YoY Change	65.21%	62.18%	127.8%
Cash From Operating Activities	-$1.541M	-$2.165M	-$1.786M
YoY Change	75.64%	21.21%	-7.46%
INVESTING ACTIVITIES
Capital Expenditures	$57.64K	-$163.5K	-$288.0K
YoY Change	-129.75%	-43.25%	860.13%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$57.64K	-$163.5K	-$288.0K
YoY Change	-70.25%	-43.25%	860.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.700M	-1.500M	-2.300M
YoY Change	-34.27%	-34.78%	-117.94%
NET CHANGE
Cash From Operating Activities	-1.541M	-2.165M	-1.786M
Cash From Investing Activities	-57.64K	-163.5K	-288.0K
Cash From Financing Activities	-1.700M	-1.500M	-2.300M
Net Change In Cash	-3.298M	-3.828M	-4.374M
YoY Change	-9.8%	-12.48%	-140.28%
FREE CASH FLOW
Cash From Operating Activities	-$1.541M	-$2.165M	-$1.786M
Capital Expenditures	$57.64K	-$163.5K	-$288.0K
Free Cash Flow	-$1.599M	-$2.001M	-$1.498M
YoY Change	133.85%	33.61%	-21.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001602078
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38355
	dei	Entity Registrant Name EntityRegistrantName	Nemaura Medical Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5027260
	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Manhattan
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	646
	dei	Local Phone Number LocalPhoneNumber	416-8000
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	NMRD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24103196	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10109650	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17749233	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1934164	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	750167	usd
CY2022Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	0	usd
CY2022Q1	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	101297	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1909967	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	1487771	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	13953781	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	20088468	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	521817	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	532508	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1427150	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1480980	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1948967	usd
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2013488	usd
CY2022Q3	us-gaap	Assets Assets	15902748	usd
CY2022Q1	us-gaap	Assets Assets	22101956	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	301104	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	136310	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	397764	usd
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	998622	usd
CY2022Q3	nmrd	Foreign Currency Contract ForeignCurrencyContract	2177458	usd
CY2022Q1	nmrd	Foreign Currency Contract ForeignCurrencyContract	440196	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	122381	usd
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	17398654	usd
CY2022Q1	us-gaap	Notes Payable Current NotesPayableCurrent	19188724	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	70980	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	259256	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20468341	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20582912	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	3490589	usd
CY2022Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2022Q3	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	955916	usd
CY2022Q1	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1052960	usd
CY2022Q3	us-gaap	Liabilities Liabilities	24914846	usd
CY2022Q1	us-gaap	Liabilities Liabilities	21635872	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24102866	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24102866	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24102866	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24102866	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	24103	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	24103	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38295775	usd
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	38295775	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45789250	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37731476	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1542726	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-122318	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-9012098	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15902748	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22101956	usd
CY2022Q3	us-gaap	Revenues Revenues	74027	usd
CY2021Q3	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	74027	usd
	us-gaap	Revenues Revenues	0	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	72357	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-0	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	72357	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-0	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1670	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	0	usd
	us-gaap	Gross Profit GrossProfit	1670	usd
	us-gaap	Gross Profit GrossProfit	0	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	257061	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286886	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	587116	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	575370	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2319972	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1427916	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4200910	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2760102	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2577033	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	1714802	usd
	us-gaap	Operating Expenses OperatingExpenses	4788026	usd
	us-gaap	Operating Expenses OperatingExpenses	3335472	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2575363	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1714802	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4786356	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3335472	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1503114	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1779462	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3271418	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3502517	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4078477	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3494264	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8057774	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6837989	usd
CY2022Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-957471	usd
CY2021Q3	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.15
	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.33
	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.29
CY2022Q3	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	24102866	shares
CY2021Q3	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	23308049	shares
	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	24102866	shares
	nmrd	Weighted Average Number Of Shares Outstanding WeightedAverageNumberOfSharesOutstanding	23209514	shares
CY2021Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-107151	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-1420408	usd
	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-117857	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5053948	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3601415	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9478182	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6955846	usd
CY2022Q3	nmrd	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.17
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3958150	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-957471	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-4078477	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-9012098	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7967399	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-107151	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-3494264	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	4365984	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-1420408	usd
	us-gaap	Profit Loss ProfitLoss	-8057774	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-9012098	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	8358172	usd
	nmrd	Exercise Of Warrants Amount ExerciseOfWarrantsAmount	2963658	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-117857	usd
	us-gaap	Profit Loss ProfitLoss	-6837989	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	4365984	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8057774	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6837989	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	172680	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	81691	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3271419	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3502517	usd
	nmrd	Change In Fair Value Of Foreign Currency Contract ChangeInFairValueOfForeignCurrencyContract	1737263	usd
	nmrd	Change In Fair Value Of Foreign Currency Contract ChangeInFairValueOfForeignCurrencyContract	270400	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1183997	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	94945	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	422197	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	264604	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	164794	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-102302	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-223678	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	652349	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-160662	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	151717	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-294288	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	469785	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4549084	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3476079	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	144343	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	47426	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	27879	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	418794	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	208945	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	220035	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-381167	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-686255	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	4700000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2963658	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6274282	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3800000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1574282	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-836342	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1135050	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-98499	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7639583	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5097175	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17749233	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31865371	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10109650	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26768196	usd
	nmrd	Release Of Prepayment From Equity Compensation ReleaseOfPrepaymentFromEquityCompensation	0	usd
	nmrd	Release Of Prepayment From Equity Compensation ReleaseOfPrepaymentFromEquityCompensation	50000	usd
	nmrd	Monitoring Fees Added To Notes Payable MonitoringFeesAddedToNotesPayable	1108896	usd
	nmrd	Monitoring Fees Added To Notes Payable MonitoringFeesAddedToNotesPayable	0	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45789250	usd
CY2022Q3	us-gaap	Cash Cash	10109650	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zOIKFRmzOlfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span style="text-decoration: underline"><span id="xdx_8B3_zYw8R9CiZ2V3">Use of Estimates</span></span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying Notes. Actual results could differ materially from those estimates. The Company’s most significant estimates include the useful life of intangible assets, valuation of foreign currency contract and valuation allowance on deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif">Our estimates are often based on complex judgments, probabilities and assumptions that management believes to be reasonable, but that are inherently uncertain and unpredictable. It is also possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. For a complete discussion of our critical accounting policies, see the “Critical Accounting Policies” section of the Management’s Discussion & Analysis in our 2022 Form 10-K.</span> </p>
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2014Q1	us-gaap	Advance Royalties AdvanceRoyalties	1000000	gbp
CY2022Q3	us-gaap	Advance Royalties AdvanceRoyalties	1120000	usd
CY2022Q1	us-gaap	Advance Royalties AdvanceRoyalties	1310000	usd
CY2022Q3	us-gaap	Deferred Revenue DeferredRevenue	71000	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	259000	usd
	nmrd	Related Party Transaction Due From To Related Partie RelatedPartyTransactionDueFromToRelatedPartie	-101297	usd
	nmrd	Related Party Transaction Due From To Related Partie RelatedPartyTransactionDueFromToRelatedPartie	148795	usd
CY2022	nmrd	Related Party Transaction Due From To Related Partie RelatedPartyTransactionDueFromToRelatedPartie	148795	usd
	nmrd	Amounts Invoiced By Pharma To Ddl AmountsInvoicedByPharmaToDdl	1833706	usd
	nmrd	Amounts Invoiced By Pharma To Ddl AmountsInvoicedByPharmaToDdl	1115748	usd
CY2022	nmrd	Amounts Invoiced By Pharma To Ddl AmountsInvoicedByPharmaToDdl	3245985	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-2437	usd
	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-2495	usd
CY2022	nmrd	Amounts Invoiced By Ddl To Pharma AmountsInvoicedByDdlToPharma	-2495	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	-1695999	usd
	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	-1770942	usd
CY2022	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	-3492962	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	88408	usd
	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	5340	usd
CY2022	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	-620	usd
	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	122381	usd
	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-503554	usd
CY2022	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-101297	usd
CY2021Q1	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	15000	usd
CY2022Q3	us-gaap	Capital Leases Future Minimum Payments Receivable In Two Years CapitalLeasesFutureMinimumPaymentsReceivableInTwoYears	17398654	usd
CY2022Q3	us-gaap	Capital Leases Future Minimum Payments Receivable In Three Years CapitalLeasesFutureMinimumPaymentsReceivableInThreeYears	3490589	usd
CY2022Q3	us-gaap	Capital Leases Future Minimum Payments Receivable Due Thereafter CapitalLeasesFutureMinimumPaymentsReceivableDueThereafter	20889243	usd
	nmrd	Warrants Exercised WarrantsExercised	0	shares
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0	shares
	nmrd	Warrants Exercised WarrantsExercised	366892	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2963658	usd
CY2021Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1573098	usd
	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	0	shares
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4078477	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3494264	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8057774	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6837989	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24102866	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23308049	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24102866	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23209514	shares
CY2022Q3	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.17
CY2021Q3	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.15
	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.33
	nmrd	Basic And Diluted Loss Per Share BasicAndDilutedLossPerShare	-0.29
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1573098	usd
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1940740	usd
CY2022Q2	us-gaap	Redemption Premium RedemptionPremium	2000000	usd

Files In Submission

Name	View Source	Status
0001079973-22-001446-index-headers.html	Edgar Link	pending
0001079973-22-001446-index.html	Edgar Link	pending
0001079973-22-001446.txt	Edgar Link	pending
0001079973-22-001446-xbrl.zip	Edgar Link	pending
ex10x2.htm	Edgar Link	pending
ex10x3.htm	Edgar Link	pending
ex10x4.htm	Edgar Link	pending
ex31x1.htm	Edgar Link	pending
ex31x2.htm	Edgar Link	pending
ex32x1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmra_10q-093022.htm	Edgar Link	pending
nmrd-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
nmrd-20220930_lab.xml	Edgar Link	unprocessable
nmrd-20220930_pre.xml	Edgar Link	unprocessable
nmra_10q-093022_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nmrd-20220930_cal.xml	Edgar Link	unprocessable
nmrd-20220930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMRD
Nemaura Medical Inc. Stock $nmrd

2022 Q4 Form 10-Q Financial Statement

#000107997322001446 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD Nemaura Medical Inc. Stock $nmrd

2022 Q4 Form 10-Q Financial Statement

#000107997322001446 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD
Nemaura Medical Inc. Stock $nmrd